Header Logo

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply.

Sands BE, Schreiber S, Lirio RA. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply. N Engl J Med. 2020 01 02; 382(1):93-94.

View in: PubMed